JP2007016035A5 - - Google Patents

Download PDF

Info

Publication number
JP2007016035A5
JP2007016035A5 JP2006209503A JP2006209503A JP2007016035A5 JP 2007016035 A5 JP2007016035 A5 JP 2007016035A5 JP 2006209503 A JP2006209503 A JP 2006209503A JP 2006209503 A JP2006209503 A JP 2006209503A JP 2007016035 A5 JP2007016035 A5 JP 2007016035A5
Authority
JP
Japan
Prior art keywords
peptidomimetic according
residue
aminobenzoic acid
peptidomimetic
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006209503A
Other languages
English (en)
Other versions
JP2007016035A (ja
JP4138826B2 (ja
Filing date
Publication date
Priority claimed from US08/371,682 external-priority patent/US5705686A/en
Priority claimed from US08/451,839 external-priority patent/US5834434A/en
Priority claimed from US08/582,076 external-priority patent/US6011175A/en
Application filed filed Critical
Publication of JP2007016035A publication Critical patent/JP2007016035A/ja
Publication of JP2007016035A5 publication Critical patent/JP2007016035A5/ja
Application granted granted Critical
Publication of JP4138826B2 publication Critical patent/JP4138826B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Claims (13)

  1. 式:
    CβX
    [式中、
    Cは3−メルカプト−2−アミノ−プロピル基であり;
    Xはアミノ酸であり(ただし、Xはフェニルアラニン、ロイシン又はイソロイシンではない);
    βは、置換されていてもよいアミノ安息香酸又は置換されていてもよいアミノナフトエ酸の残基であり、
    Xとβは、相互に、Xのアミノ基とβのカルボキシル基により形成されるアミド結合を介して連結され;
    Cとβは、相互に、Cのプロピル基とβのアミノ基とを介して連結されている]
    で示されるペプチド模倣体。
  2. βが2−フェニル−4−アミノ安息香酸の残基である、請求項1記載のペプチド模倣体。
  3. βが置換4−アミノ安息香酸の残基である、請求項1記載のペプチド模倣体。
  4. Xがメチオニンである、請求項1記載のペプチド模倣体。
  5. βがアミノ安息香酸の残基である、請求項1記載のペプチド模倣体。
  6. Xがメチオニンである、請求項5記載のペプチド模倣体。
  7. βが置換4−アミノ安息香酸の残基である、請求項6記載のペプチド模倣体。
  8. βが2−フェニル−4−アミノ安息香酸又は2−ナフチル−4−アミノ安息香酸の残基である、請求項7記載のペプチド模倣体。
  9. 4−アミノ安息香酸の残基がフェニル環の2−及び/又は3−位置においてアルキル、アルコキシ、アリール若しくはナフチル基、又は複素環若しくはヘテロ芳香環によって置換される、請求項7記載のペプチド模倣体
  10. 請求項1から9の何れか1項に記載のペプチド模倣体と、製薬的に受容されるキャリヤーとを含む、薬剤組成物
  11. 請求項1から9の何れか1項に記載のペプチド模倣体の有効量を活性成分として含む、ファルネシルトランスフェラーゼを阻害するための薬剤組成物
  12. 請求項1から9の何れか1項に記載のペプチド模倣体の有効量を活性成分として含む、癌を治療するための薬剤組成物
  13. 請求項1から9の何れか1項に記載のペプチド模倣体の有効量を活性成分として含む、癌を治療するための薬剤組成物
JP2006209503A 1995-01-12 2006-08-01 プレニルトランスフェラーゼの阻害剤 Expired - Fee Related JP4138826B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/371,682 US5705686A (en) 1993-05-18 1995-01-12 Inhibition of farnesyl transferase
US08/451,839 US5834434A (en) 1993-05-18 1995-05-30 Inhibitors of farnesyltransferase
US55255495A 1995-11-03 1995-11-03
US08/582,076 US6011175A (en) 1993-05-18 1996-01-02 Inhibition of farnesyltransferase

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP52188496A Division JP3929069B2 (ja) 1995-01-12 1996-01-11 プレニルトランスフェラーゼの阻害剤

Publications (3)

Publication Number Publication Date
JP2007016035A JP2007016035A (ja) 2007-01-25
JP2007016035A5 true JP2007016035A5 (ja) 2007-03-08
JP4138826B2 JP4138826B2 (ja) 2008-08-27

Family

ID=27503084

Family Applications (2)

Application Number Title Priority Date Filing Date
JP52188496A Expired - Lifetime JP3929069B2 (ja) 1995-01-12 1996-01-11 プレニルトランスフェラーゼの阻害剤
JP2006209503A Expired - Fee Related JP4138826B2 (ja) 1995-01-12 2006-08-01 プレニルトランスフェラーゼの阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP52188496A Expired - Lifetime JP3929069B2 (ja) 1995-01-12 1996-01-11 プレニルトランスフェラーゼの阻害剤

Country Status (6)

Country Link
EP (1) EP0794789A4 (ja)
JP (2) JP3929069B2 (ja)
AU (1) AU4915796A (ja)
CA (1) CA2207252C (ja)
MX (1) MX9705273A (ja)
WO (1) WO1996021456A1 (ja)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003342B1 (en) 1990-04-18 2011-08-23 Board Of Regents, The University Of Texas System Method for identifying farnesyl transferase inhibitors
US5962243A (en) * 1990-04-18 1999-10-05 Board Of Regents, The University Of Texas System Methods for the identification of farnesyltransferase inhibitors
US6117641A (en) 1996-04-11 2000-09-12 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents and uses related thereto
US6727082B1 (en) 1996-04-11 2004-04-27 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
EP0892854B1 (en) 1996-04-11 2002-07-03 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
US5773455A (en) * 1996-06-28 1998-06-30 Biomeasure, Incorporated Inhibitors of prenyl transferases
US5990277A (en) * 1996-09-03 1999-11-23 Yissum Research Development Company Of The Herbrew University Of Jerusalem Semipeptoid farnesyl protein transferase inhibitors and analogs thereof
US20030060434A1 (en) 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
GB2323841A (en) * 1997-04-04 1998-10-07 Ferring Bv Group Holdings Pyridine derivatives with anti-tumor and anti-inflammatory activity
GB2323842A (en) * 1997-04-04 1998-10-07 Ferring Bv Pyridine derivatives
PH11998001072B1 (en) * 1997-05-07 2006-11-21 Univ Pittsburgh Inhibitors of protein isoprenyl transferases
FR2780974B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
US6423519B1 (en) 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
DE19851714A1 (de) * 1998-11-05 2000-05-11 Knoell Hans Forschung Ev Amide des Cysteins als Inhibitoren der Farnesyltransferase
EP2172222A3 (en) * 2004-04-26 2010-06-23 Ono Pharmaceutical Co., Ltd. Novel BLT2-mediated disease, BLT2-binding agent and compound
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007121484A2 (en) 2006-04-19 2007-10-25 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
RS58936B1 (sr) 2007-01-10 2019-08-30 Msd Italia Srl Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
US8293769B2 (en) 2007-05-21 2012-10-23 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 縮合複素環式化合物およびそれらの使用
MX2012004377A (es) 2009-10-14 2012-06-01 Merck Sharp & Dohme Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CA2791613A1 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN108676800B (zh) 2010-08-17 2022-11-11 瑟纳治疗公司 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP2836482B1 (en) * 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
RU2660349C2 (ru) 2012-11-28 2018-07-05 Мерк Шарп И Доум Корп. Композиции и способы для лечения злокачественной опухоли
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CA2927920A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
AU2018252546A1 (en) 2017-04-13 2019-10-10 Sairopa B.V. Anti-SIRPα antibodies
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2023250063A1 (en) * 2022-06-22 2023-12-28 Bioventures, Llc Method of mitigating radiation injury with geranylgeranyl transferase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602098A (en) * 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase

Similar Documents

Publication Publication Date Title
JP2007016035A5 (ja)
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
JP2008509166A5 (ja)
MX2011012628A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
WO2007085833A3 (en) Pyrimidine derivatives
JP2006509749A5 (ja)
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
MX2009011089A (es) Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
CA2615921A1 (en) Hepatitis c inhibitor peptide analogs with a quinoline or a thienopyridine moiety
TN2012000125A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
WO2007146248A3 (en) Stable laquinimod preparations
JP2009501732A5 (ja)
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
EP2682387A3 (en) C7-fluoro substituted tetracycline compounds
JP2011529502A5 (ja)
MY148847A (en) 5-hydroxymethyl-oxazolidin-2-one derivatives
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
PE20080852A1 (es) Polimorfos de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
NZ596820A (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
WO2008000421A3 (en) Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors
JP2004532828A5 (ja)